Jun 04,2023

Massive Bio Joins CancerX as Founding Member to Accelerate Innovation and AI Implementation in Cancer Care

Massive Bio, a globally recognized leader in the oncology space, has proudly announced its appointment as a founding member of CancerX, a groundbreaking initiative endorsed by The White House. Spearheaded by the rejuvenated Cancer Moonshot initiative, CancerX is co-hosted by Moffitt Cancer Center and Digital Medicine Society (DiMe), bringing together diverse stakeholders to foster greater equity and reduce financial toxicity in cancer care and research.

View Analyst & Ambassador Comments
Go to original news
Jun 05,2023

Aster Insights announces that The University of Kansas Cancer Center will join the Oncology Research Information Network (ORIEN)

Aster Insights (formerly known as M2GEN), the leading provider of technology-enabled data and analytics solutions for oncology discovery, today announced The University of Kansas Cancer Center will join its Oncology Research Information Exchange Network (ORIEN). The KU Cancer Center will be the latest NCI-designated cancer center to join ORIEN, which is comprised of 18 cancer centers across the U.S. dedicated to collaborative research to accelerate cancer discovery and development. Launched in 2014, ORIEN is the largest and longest-running academic cancer research consortium of its kind in the United States. ORIEN members participate in the Total Cancer Care (TCC) protocol, the largest lifetime-consented patient research program in oncology, utilizing deep clinical and genomic data to best support patient care, research, and discovery.

COLLABORATION PARTNERSHIP

#institution

#rwd

View Analyst & Ambassador Comments
Go to original news
May 31,2023

Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study

Only around 20–30% of patients with non-small-cell lung cancer (NCSLC) have durable benefit from immune-checkpoint inhibitors. Although tissue-based biomarkers (eg, PD-L1) are limited by suboptimal performance, tissue availability, and tumour heterogeneity, radiographic images might holistically capture the underlying cancer biology. In this study the researchers aimed to investigate the application of deep learning on chest CT scans to derive an imaging signature of response to immune checkpoint inhibitors and evaluate its added value in the clinical context. At the end, this proof-of-concept study shows that automated profiling of radiographic scans through deep learning can provide orthogonal information independent of existing clinicopathological biomarkers, bringing the goal of precision immunotherapy for patients with NSCLC closer.

CLINICAL STUDY

#ml

View Analyst & Ambassador Comments
Go to original news
Jun 01,2023

Startup Ezra wins FDA clearance for AI that enhances MRIs

Ezra today announced it received FDA 510(k) clearance for its Ezra Flash AI platform that enhances the quality of MR images. Ezra’s technology leverages AI across all three key components of the cancer screening process, which includes imaging, analysis and reporting. Ezra Flash AI enables Ezra to increase MR image quality, Ezra Prostate AI assists radiologists in the analysis of MR images of the prostate and Ezra Reporter AI creates an easily digestible translation of radiology reports that assist medical professionals in communicating screening results to people. Ezra Flash has so far received FDA clearance for use in the brain. The company said that its full Boyd MRI, which previously took one hour, is now available as a 30-minute MRI scan. Ezra’s ultimate goal is to reduce the time to 15 minutes.

REGULATORY FDA

#ai/software

View Analyst & Ambassador Comments
Go to original news
May 31,2023

InHealth partners with Qure.ai to enhance quality of Telereporting services with AI-powered chest X-ray solution

InHealth, the UK’s largest specialist provider of diagnostic and healthcare solutions, has announced a partnership with Qure.ai, a market leader in medical artificial intelligence (AI) solutions. Through this partnership, InHealth will be deploying Qure.ai‘s AI solution to aid in the classification of chest X-rays into normal and abnormal exams. The solution will be deployed across InHealth’s entire Tele-reporting service arm to help enhance the quality and accuracy of reporting using AI. Qure.ai‘s chest X-ray software can detect multiple lung abnormalities in under one minute. It can accurately assess radiological findings presumptive of a host of lung diseases, including lung cancer, pneumonia, COPD, TB, and heart failure, among others.

COLLABORATION PARTNERSHIP

#institution

#ai/software

#telehealth

View Analyst & Ambassador Comments
Go to original news
May 18,2023

It’s a match! Connecting patients to clinical trials with AI

One of the biggest pain points in clinical trials is patient recruitment. Clinical trials often have strict eligibility criteria that look for suitable subjects who are healthy enough to participate. People who stop responding to existing therapies always look for the next best thing, and sometimes the only option left is a clinical trial, says Belong.Life’s chief technology officer Irad Deutsch. Belong.Life offers patient support across various therapy areas, but there is a high demand for clinical trials among oncology patients. AI trial matching platforms also increase awareness among physicians, says Dr Michel van Harten, CEO at myTomorrows, which recently released a physician-focused clinical trial search tool TrialSearch AI. While AI matching platforms are efficient, they are far from being perfect, and human oversight is still a crucial element. Deutsch explains that Belong.Life’s Natural Language Processing engine has been trained for seven years, and while most of the suggested trials are appropriate for patients, sometimes there is still a need for fine tuning.

#ai/software

View Analyst & Ambassador Comments
Go to original news
May 23,2023

Revolutionary ChatGPT-Powered Chatbot Platform at ASCO 2023

Massive Bio, a leading provider of personalized oncology solutions, will be participating in the prestigious American Society of Clinical Oncology (ASCO) annual meeting from June 2nd to June 6th. The event serves as a platform for sharing groundbreaking advancements in cancer care, and Massive Bio is excited to unveil its innovative ChatGPT-powered chatbot platform featuring AskFiona AI and DrArturo AI. With AskFiona AI as the initial point of contact, patients can receive comprehensive insights into clinical trials, understanding their purpose and assessing eligibility. The platform seamlessly escalates patients to DrArturo AI, providing tailored information about specific clinical trials, including treatment details, schedules, nearest treatment facilities, and more.

PRODUCT

#chatbot

#ai/software

View Analyst & Ambassador Comments
Go to original news
May 24,2023

New Data Presented at ATS 2023 Reinforce Clinical Utility of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer

Veracyte, Inc. (Nasdaq: VCYT) today announced new data suggesting its novel genomic tests may positively impact diagnosis and care for patients being evaluated for interstitial lung disease (ILD) or lung cancer. The findings were presented at ATS 2023, the annual meeting of the American Thoracic Society, which is being held May 21-24 in Washington, D.C.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
May 15,2023

Merck to Present New Research Demonstrating Significant Progress in the Treatment of Certain Earlier Stage Cancers at 2023 ASCO Annual Meeting

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that data for four approved medicines and two pipeline candidates in more than 25 types of cancer will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from June 2-6.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
May 17,2023

Aitia Enters into Multi-Year AI-Driven Drug Discovery and Drug Simulation Collaboration with Servier for Pancreatic Cancer

Aitia, the leader in the development and application of Causal AI and “Digital Twins” to discover and develop new drugs, today announced a collaboration with Servier to create new Gemini Digital Twins to help in the fight against Pancreatic Cancer. Under the terms of the collaboration, Aitia and Servier will work together to focus on translational questions to discover, validate, and strive to develop novel drug targets and drug candidates in pancreatic cancer through utilization of Aitia’s Pancreatic Cancer Digital Twins and Servier’s pre-clinical assays, therapeutic creation platforms, and expertise. Servier will receive an exclusive option to research, develop, and commercialize products directed to several novel drug targets.

COLLABORATION PARTNERSHIP

#r&d

View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY